July 7th 2024
The combination of englumafusp alfa and glofitamab showed a BOR of 67.0% and CR rate of 57.0% in second-line settings. In third-line settings, the BOR was 65.7% and the CR rate was 52.8%.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Zandelisib on Intermittent Dosing Schedule is Safe in R/R B-Cell Malignancies
August 2nd 2022Findings from a phase 1 study concluded zandelisib given to patients with relapsed/refractory B-cell malignancies at 60 mg once daily in an intermittent dosing schedule reflected in a positive safety profile.
Read More
Novel Anti-CD19 CAR T-Cell Therapy Shows Efficacy in Multiple BCL Subtypes
July 30th 2022Manali Kamdar, MD, MBBS, discusses the efficacy and tolerability of a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell lymphoma.
Watch
FDA Grants Fast Track and Rare Pediatric Disease Designations for WU-CART-007 in T-ALL/LBL
July 20th 2022The FDA has granted fast track designation and rare pediatric disease designation for WU-CART-007 as treatment for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
Read More
Behind the FDA Approval: Liso-Cel for R/R Large B-Cell Lymphoma
June 30th 2022In an interview with Targeted Oncology, Manali Kamdar, discussed the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma, and how community oncologists should approach patient referrals and post-treatment care.
Read More
Positive Outcomes of Novel Cellular Therapies Are Seen in Long Relapse, DLBCL
June 17th 2022Patients with relapsed/refractory diffuse large B-cell lymphoma who benefit most from novel therapies vs patients who would likely do well with standard treatment were identified among all curatively treated patients in Sweden from 2007 to 2014.
Read More
Six-Year Survival Extends With Brentuximab Vedotin Plus Chemotherapy in Hodgkin Lymphoma
June 4th 2022Therapy with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, in patients with previously untreated stage III/IV classical Hodgkin lymphoma.
Read More
Anti-CD19 CAR T Cells for the Treatment of Relapsed/Refractory NHL
June 1st 2022In an interview with Targeted Oncology, Manali Kamdar, MD, discussed the current relapsed/refractory B-cell non-Hodgkin lymphoma space, along with data from the phase 1 clinical trial of an anti-CD19 CAR T-cell product for these patients.
Read More
PI3K Inhibitors and CAR T-Cell Therapy Find Their Niche in Indolent B-Cell Lymphomas
May 16th 2022In relapse/refractory follicular lymphoma, promising results have been observed with PI3K inhibitors and are encouraging because of the less than optimal outcome associated with Bruton's tyrosine kinase inhibitors.
Read More